Special Issue

Molecular Pathogenesis and Management of Anaplastic Large Cell Lymphoma

Message from the Guest Editor

Dear colleagues, Anaplastic large cell lymphoma (ALCL) includes distinct subgroups of peripheral mature T-cell lymphomas defined by their strong expression of the CD30 antigen and commonly composed of large pleomorphic cells. The defined entities in the most recent 2017 World Health Organization classification of hematopoietic and lymphoid tissues include systemic ALK-positive (ALK+) and ALK-negative (ALK-) ALCL, cutaneous ALCL, and breast implant-associated ALCL. Each entity is defined based on distinct genetic aberrations, epidemiological characteristics, clinical presentations, and prognosis. The presence of an *ALK* rearrangement resulting in the aberrant expression of the ALK fusion oncoprotein is a genetically defining aberration for ALK+ ALCL, which more frequently affects children and young adults and has better prognosis compared to ALK- ALCL. Notably, within the ALK- ALCL group, subsets with mutually exclusive cytogenetic alterations have been identified (TP63r+, IRF4/DUSP22r+, and triple-negative ALCL) with prognostic implications.

Guest Editor

Dr. Vasiliki Leventaki

Department of Pathology, Children's Hospital of Wisconsin & Medical College of Wisconsin, Milwaukee, WI 53226, USA

Deadline for manuscript submissions

closed (1 June 2022)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/63701

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)